Paolo Caimi, Md
Clinical trials sponsored by Paolo Caimi, Md, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug combo aims to tackle tough lymphoma Results expected Nov 2026 (estimated)
-
Experimental immune cell cocktail targets tough lymphoma
Disease control Recruiting nowThis early-phase trial tests a new treatment for people with B-cell non-Hodgkin lymphoma that has not responded to at least two prior therapies. Participants receive donor immune cells (NK cells) along with two antibody drugs (rituximab and tafasitamab) and a support drug (IL-2) …
Phase 1 • Sponsor: Paolo Caimi, MD • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Engineered immune cells take aim at stubborn blood cancers
Disease control Recruiting nowThis early-phase trial is testing a new type of CAR-T cell therapy called LMY-920 for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or stopped responding to other treatments. The therapy uses a protein called BAFF to help th…
Phase 1 • Sponsor: Paolo Caimi, MD • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC